In November 2020, SynOx acquired from Roche an exclusive worldwide licence to emactuzumab, a potentially best-in-class CSF-1R therapeutic antibody. Emactuzumab has a well-tolerated safety profile and showed remarkable efficacy in patients suffering from diffuse tenosynovial giant cell tumour (TGCT), a rare disease that causes significant pain and disability. SynOx is led by an experienced team of industry professionals with a successful track record of developing and bringing products to commercialisation.

Management Team

RBSO_JC_2106_000004 V2Hi

Ray Barlow

Chief Executive Officer

Ray was appointed as CEO of SynOx Therapeutics on 1st May 2021. Ray has over 20 years’ experience of the biopharmaceutical industry gained through leadership positions in scientific, clinical, commercial, and executive roles. Ray has diverse experience gained in global pharmaceutical companies (AstraZeneca, J&J and Amgen), publicly listed biotechs (Emergent BioSolutions Inc, Crucell N.V., e-Therapeutics PLC and Kiadis N.V.) and private companies such as Asterion Limited.

Ray has very strong corporate development experience, right across the value chain and has led and closed numerous M&A, licensing, commercial, manufacturing, equity-based and IP-based deals collectively worth multiple billions of dollars. Prior to his industrial career, Ray completed a PhD at Manchester University, UK and did postdoctoral research at McGill University, Canada.

Axel Mescheder

Chief Medical Officer

Axel joined SynOx Therapeutics on 1st June 2021 as Chief Medical Officer, bringing over 25 years of clinical development and regulatory experience at biotechnology and pharmaceutical companies. He has a track record of implementing and driving clinical development programs, resulting in successful product registrations or label extensions in both Europe and the United States. His expertise includes the therapeutic areas of oncology, immunology, and inflammation.

He held a range of senior management positions at international pharmaceutical and biotechnology companies including Hoffmann-La Roche, and MorphoSys and within the CRO industry (Medpace). His responsibilities in these functions included, among others, clinical development, medical and scientific meetings with U.S. FDA, EMA and national European agencies, commercialization and registration activities, as well as organizing and chairing of international conferences, investigator meetings and participation in drug safety boards.

In addition to his position at SynOx Therapeutics, he is member of leading international medical associations including ASCO, ESMO, ESCMID, DGPharMed/ IFAPP and he supports BioM/Martinsried as a mentor for biotech start-up companies.

Axel is a board-certified M.D. from the University of Kiel (Germany), with a medical license and full specialization in Pharmacology and Toxicology. He is author and co-author of peer-reviewed publications and presented at various international medical, scientific and business conferences.

M_0178 - Preferred photo - Square
BNSO_JC_1506_000113 V2Hi

Broes Naeye

Chief Technology Officer

Broes joined SynOx Therapeutics on 1st June 2021 with more than 10 years of experience in development and commercialization of biopharmaceuticals. Most recently, he served as Global Product Supply Lead at Sanofi, where he was responsible for the global supply of Dupixent®. Previously, he worked as Head of Commercial Supply and CMC Project Lead at Ablynx. Broes graduated as a pharmacist and holds a PhD in biochemistry from the University of Ghent, Belgium.

Sarah Clare

Director of Finance and Operations

Sarah joined SynOx Therapeutics on 1st July 2021. She is a Chartered Accountant with over 10 years’ experience in finance. She trained at Blick Rothenberg in London and has since gained experience across a wide range of management, operations and compliance. She was responsible for technical financial reporting at a large multinational group before more recently focussing on life sciences, taking on more responsibility across the finance, admin and corporate governance frameworks in an AIM-listed environment. Sarah also attended Imperial College London where she attained a first class BSc (Hons) in Biology and Business Management.

SCSO_JC_1506_000174 V2Hi

Board of Directors

Ton Logtenberg

Non-Executive Chairman

Ton joined SynOx Therapeutics on 1st May 2021 as Non-Executive Director and Chairman of the Board of Directors. Ton has over 25 years’ experience in the biopharmaceutical industry as a co-founder and Chief Scientific Officer of Crucell N.V. and founder, President and CEO of Merus N.V.

Ton has extensive experience in founding biotech companies and taking them from start-up to public listings on the Nasdaq and Euronext exchanges and beyond. Ton completed a PhD in Immunology at Utrecht University, the Netherlands and undertook postdoctoral research at Columbia University in New York. Ton has held a professorship in Immuno-biotechnology at Utrecht University and is currently a professor in Entrepreneurship in the Life Sciences at the same University.

TL_SynOx_JC_2806_000083 V2Hi
RBSO_JC_2106_000094 V1Hi

Ray Barlow

Chief Executive Officer

Ray was appointed as CEO of SynOx Therapeutics on 1st May 2021. Ray has over 20 years’ experience of the biopharmaceutical industry gained through leadership positions in scientific, clinical, commercial, and executive roles. Ray has diverse experience gained in global pharmaceutical companies (AstraZeneca, J&J and Amgen), publicly listed biotechs (Emergent BioSolutions Inc, Crucell N.V., e-Therapeutics PLC and Kiadis N.V.) and private companies such as Asterion Limited.

Ray has very strong corporate development experience, right across the value chain and has led and closed numerous M&A, licensing, commercial, manufacturing, equity-based and IP-based deals collectively worth multiple billions of dollars. Prior to his industrial career, Ray completed a PhD at Manchester University, UK and did postdoctoral research at McGill University, Canada.

Dirk Kersten

Dirk is a General Partner at Forbion and manages the Forbion Growth Opportunities Fund. Dirk is a physicist by training and previously worked as a Partner at Gilde Healthcare Partners, where he led their Boston/US operations. Furthermore Dirk was a Managing Director at INKEF Capital responsible for all life sciences investment activities. Dirk led a series of investments in Europe and the US, including: Dyne Therapeutics (NASDAQ: DYN) Ascendis Pharma (NASDAQ: ASND), Profibrix (acquired by MEDCO), Lanthio Pharma (acquired by Morphosys), Nightbalance (acquired by Philips), Audion Therapeutics (private).

blurred office background, bokeh background, conference hall, circle table
Michaël Vlemmix

Michaël Vlemmix

Michaël is part of Gimv’s Health & Care Life Sciences team for more than 3 years and is currently a Principal. Next to being a Bio-Engineer in Cell & Gene Biotechnology complemented with a Master in Management, he has a background in investment banking and start-up experience. He serves on the board of Precirix, a radiopharmaceutical company. Gimv is a European investment company, listed on Euronext Brussels with 40 years' experience in private equity & venture capital and has currently EUR 2 billion of assets under management.

Jacob Gunterberg

Partner with HealthCap. Prior to joining HealthCap in 2007, Mr. Gunterberg gained 14 years of investment banking experience with a focus on healthcare related transactions. Mr. Gunterberg received his M. Sc. in Business Administration and Economics from the University of Lund and has also studied at the University of St. Gallen.

HealthCap is one of the largest specialized providers of venture capital within life sciences in Europe. Since the start in 1996, HealthCap has backed and built more than 100 companies. HealthCap’s investment strategy focuses on diseases with high unmet medical needs and breakthrough therapies which have the potential to be transformative and improve the lives of patients suffering from these conditions.

Jacob Gunterberg_photo
francesco-de-rubertis

Francesco De Rubertis

Francesco is a co-founder and Partner at Medicxi. Prior to Medicxi, Francesco was a Partner at Index Ventures for 19 years, having joined the firm in 1997 to launch its life sciences practice. Under his leadership, the asset-centric approach to life sciences investing was conceived and adopted. Francesco currently serves on the boards of a number of portfolio companies, including Palladio Biosciences, Rivus Pharmaceuticals, Orexia and Inexia. Francesco received a BA in Genetics and Microbiology from the University of Pavia and a PhD Molecular Biology from the University of Geneva. He conducted postdoctoral research at the Whitehead Institute at MIT and is a CFA Charterholder. Francesco also serves on the strategic advisory board of the University of Geneva.

Professor Nick La Thangue

Nick has over 30 years of experience in biotech entrepreneurship, translational cancer science and drug development. He founded Prolifix focused on cell cycle therapeutics, where he acted as CSO and CEO until its merger with TopoTarget which led to a highly successful IPO. He founded Oxford Cancer Biomarkers, which continues to develop a portfolio of marketed precision cancer medicine tests, where he held senior positions including CEO and CSO. He has been CEO at Celleron Therapeutics developing precision cancer drugs since the company was founded. Nick is Professor of Cancer Biology at Oxford University. He is a Fellow of the Royal Society of Edinburgh, the Academy of Medical Sciences, the European Academy of Cancer Science, the Lister Institute and Professorial Fellow of Linacre College Oxford. He has over 200 publications and is an inventor on numerous patents.

Nick-La-Thangue

Our Partners

partners

SynOx is backed by experienced life sciences investors HealthCap, Medicxi, Forbion and Gimv.